Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2025 07:57 ET | Source: ZyVersa Therapeutics

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

Inflammasome inhibitors in combination with GLP-1 agonists have potential to address unmet medical needs of people living with obesity.
October 15, 2024 07:50 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZyVersa discusses trend toward add-on therapy for obesity to address metabolic complications and the role of inflammasome inhibitors on Big Biz Show.
June 26, 2024 13:00 ET | Source: DelveInsight Business Research LLP

GLP-1 Agonists Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Inc., Eccogene, AstraZeneca

New York, USA, June 26, 2024 (GLOBE NEWSWIRE) -- GLP-1 Agonists Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns...
June 14, 2024 09:00 ET | Source: PatchMD

PatchMD Releases Medical Weight Loss Resources with Expert-Reviewed Articles on GLP-1 Agonists

Las Vegas, NV, June 14, 2024 (GLOBE NEWSWIRE) -- PatchMD, a leader in innovative vitamin supplement delivery, is excited to announce the release of a series of comprehensive resources designed to...